Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Vandoeuvre Les Nancy – page 27

584 clinical trials in Vandoeuvre Les Nancy, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Vandoeuvre Les Nancy at a glance
584
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

584 trials in Vandoeuvre Les Nancy

Open in trial search

Rectal adenocarcinoma

Not yet recruiting

Study of drug combination with radiotherapy versus radiotherapy alone for locally advanced rectal cancer in patients 75 years and older

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Calcium Levofolinate
  • Sponsor:Unicancer

Acute myeloid leukaemia

Not yet recruiting

A Study of Ivosidenib and Azacitidine for Patients Over 55 with Acute Myeloid Leukemia and IDH1 Mutation in Complete Remission

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Anti-neutrophil cytoplasmic antibody positive vasculitis

Not yet recruiting

Testing avacopan added to standard treatment in patients with ANCA-associated vasculitis with severe kidney damage

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avacopan
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Chronic lymphocytic leukaemia

Not yet recruiting

Study of pirtobrutinib combined with immuno-chemotherapy for previously untreated patients with symptomatic chronic lymphocytic leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Breast cancer metastatic

Not yet recruiting

Study of tucatinib and trastuzumab for patients with HER3-mutant and HER2-not amplified metastatic breast cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab
  • Sponsor:Institut Curie

Cutaneous T-cell lymphoma

Not yet recruiting

Study of brentuximab vedotin for maintenance therapy in patients with cutaneous T-cell lymphoma after stem cell transplant

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Assistance Publique Hopitaux De Paris

Secondary progressive multiple sclerosis+1

Not yet recruiting

Study on the Safety and Effects of YTB323 and Drug Combination in Patients with Progressive Multiple Sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Colorectal cancer

Not yet recruiting

Study of 5-Fluorouracil, Panitumumab, and Sotorasib for Patients with Advanced KRAS G12C Mutated Colorectal Cancer Not Eligible for Standard Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Fondation Franc.Cancerologie Digestive

Evaluation of Methylprednisolone and Prednisone in Adult Patients with Acute Myocarditis and Reduced Heart Function

Not yet recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:Assistance Publique Hopitaux De Paris

Relapsing multiple sclerosis

Not yet recruiting

Study on the Safety and Effects of YTB323, Tocilizumab, and Cyclophosphamide in Patients with Relapsing Multiple Sclerosis Who Have Active Disease Despite Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Myocarditis

Not yet recruiting

Study on Methylprednisolone and Human Normal Immunoglobulin for Treating Fulminant Myocarditis in Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glucose
  • Sponsor:Assistance Publique Hopitaux De Paris

Renal transplant

Not yet recruiting

Study on Eplerenone for Heart Health in Kidney Transplant Patients Using Cyclosporine or Tacrolimus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Eplerenone
  • Sponsor:CHRU De Nancy

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Vandoeuvre Les Nancy

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on innovative treatments for various cancer types, including head and neck squamous cell carcinoma, multiple myeloma, and prostate cancer. Studies evaluate new therapeutic approaches and diagnostic methods.

  • Advanced cancer treatments
  • Therapeutic combinations
  • Survival outcomes

Several trials investigate novel drug combinations and targeted therapies for improving patient outcomes.

02 Autoimmune Conditions

Comprehensive research into inflammatory bowel diseases, particularly Crohn's disease and ulcerative colitis. Studies explore innovative treatments including microbiota transplantation and new biological therapies.

  • Disease management
  • Treatment efficacy
  • Long-term outcomes

Trials aim to develop more effective maintenance therapies and improve quality of life for patients.

03 Neurological Disorders

Groundbreaking research in multiple sclerosis treatment, including both progressive and relapsing forms. Studies evaluate new therapeutic approaches and disease progression markers.

  • Disease modification
  • Treatment safety
  • Clinical outcomes

Focus on developing innovative treatments for better management of neurological conditions.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.